1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Glioblastoma Multiforme (GBM) Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

SUMMARY
DelveInsight’s, “ Glioblastoma Multiforme (GBM)- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:
- A snapshot of the global Market therapeutics scenario for Glioblastoma Multiforme (GBM).
- A review of the marketed products under prescription for Glioblastoma Multiforme (GBM), regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Glioblastoma Multiforme (GBM) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Glioblastoma Multiforme (GBM) drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Glioblastoma Multiforme (GBM) drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Glioblastoma Multiforme (GBM) drugs.
- Coverage of Glioblastoma Multiforme (GBM) Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure from 2011-2015.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Glioblastoma Multiforme (GBM) key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Glioblastoma Multiforme (GBM).
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Glioblastoma Multiforme (GBM).
- API intelligence over marketed drugs for Glioblastoma Multiforme (GBM) and gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Glioblastoma Multiforme (GBM).
- Uncovering opportunities in the rapidly growing the US markets.

Table Of Contents

Glioblastoma Multiforme (GBM) Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
Table of Contents
- Indication Overview
- Marketed Drugs Assessment
- Marketed Details of Drugs by Application Type
- Marketed Details of Drugs (NDA) by Marketing Status
- Marketed Details of Drugs by Patent Expiration Timeline
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
- The API Manufacturers by the United States Drug Master File (US DMF) Status
- The API Manufacturers by the US DMF Status (Drug Specific)
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
- The API Manufacturers by the US DMF Status (Drug Specific)
- Drugs Market Data and Forecasted Sales Figures (2011-2015)
- Marketed Drugs Information
- Drugs Description
- Route of Synthesis
- Global Active Pharmaceutical Manufacturers
- Approval Status
- Patent and Exclusivity Details
- Company Overview
- Phase III Drugs Information
- Phase III Drugs Description
- The United States Drug Master Filings (US DMF)
- Discontinued Drugs Information


List of Tables

Glioblastoma Multiforme (GBM) Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Glioblastoma Multiforme (GBM) Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Glioblastoma Multiforme (GBM) Therapeutic Market, US, (Year), 2014
Glioblastoma Multiforme (GBM) Marketed Drugs, API Manufacturers by US DMF Status, 2014
Glioblastoma Multiforme (GBM) Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Glioblastoma Multiforme (GBM) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Glioblastoma Multiforme (GBM) Therapeutic Market, Global Sales (in million USD), 2014
Glioblastoma Multiforme (GBM) Marketed Drugs, API Manufacturers, Global, 2014
Glioblastoma Multiforme (GBM) Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014
Discontinued Drugs for Glioblastoma Multiforme (GBM), 2014?


List of Figures

Glioblastoma Multiforme (GBM) Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Glioblastoma Multiforme (GBM) Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Glioblastoma Multiforme (GBM) Therapeutic Market, US, (Year), 2014
Glioblastoma Multiforme (GBM) Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Glioblastoma Multiforme (GBM) Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Glioblastoma Multiforme (GBM) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Glioblastoma Multiforme (GBM) Therapeutic Market, Global Sales (in million USD), 2014
Glioblastoma Multiforme (GBM) Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Glioblastoma Multiforme-Market Insights, Epidemiology and Market Forecast-2023

Glioblastoma Multiforme-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Glioblastoma Multiforme - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Glioblastoma multiforme (GBM) - Epidemiology Forecast To 2023

Glioblastoma multiforme (GBM) - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Glioblastoma multiforme (GBM) - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Glioblastoma multiforme (GBM) in seven major markets (US, France, Germany, ...

Pilocytic Astrocytoma Global Clinical Trials Review, H2, 2016

Pilocytic Astrocytoma Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • October 2016
  • by GlobalData

Pilocytic Astrocytoma Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Pilocytic Astrocytoma Global Clinical Trials Review, H2, 2016" provides an overview of Pilocytic ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics and Autoimmune Disease Statistics in the US

  • January 2017
    152 pages
  • Cancer  

    Autoimmune Dise...  

    Dermatological ...  

  • United States  

View report >

Cancer Statistics in Australia

  • January 2017
    205 pages
  • Cancer  

    Mortality  

    Hospital  

  • Australia  

View report >

Cancer Statistics in the US

  • December 2016
    112 pages
  • Cancer  

  • United States  

    North America  

View report >

Cancer Statistics

4 months ago

Related Market Segments :

Brain Cancer

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.